116
Participants
Start Date
October 31, 2006
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2010
clofarabine
"Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days."
Mayo Clinical Hospital, Phoenix
Arizona Cancer Center, Tucson
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles
Scripps Cancer Center, San Diego
Rocky Mountain Cancer Centers, Denver
Cancer Center of Central Connecticut, Southington
Emory University School of Medicine, Atlanta
Medical College of Georgia, Augusta
Rush University Medical Center, Chicago
Beth Israel Deaconess Medical Center, Boston
University of Michigan Comprehensive Cancer Center, Ann Arbor
Mount Sinai School of Medicine, New York
Oregon Health and Science University, Portland
Penn State Hershey Medical Center, Hershey
Vanderbilt University Medical Center, Nashville
University of MD Anderson Cancer Center, Houston
Cancer Care Centers of South Texas, San Antonio
University of Utah - Huntsman Cancer Institute, Salt Lake City
Seattle Cancer Care Alliance, Seattle
West Virginia University - HSC, Morgantown
Genzyme, a Sanofi Company
INDUSTRY